Biomagnetics Diagnostics obtains handheld IOBS unit to detect pathogens

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received its first handheld integrated optical biosensor (IOBS) unit from Los Alamos National Security, LLC.

“We believe the receipt of this first integrated optical biosensor unit from Los Alamos will allow us to accelerate both our clinical trial and marketing efforts”

IOBS are a relatively new classification of pathogen detection equipment that use advanced fiber optic-based technology to detect a wide variety of human and animal pathogens. These devices are specifically designed to be field deployable and ultraportable, allowing for the rapid detection of various viral and bacterial pathogens by relatively un-trained personnel outside of the laboratory setting.

Near the end of 2009, the Company completed an agreement with Los Alamos National Security, which provides access to some of the most technologically advanced and exciting biosensor technology in existence. The version of the IOBS Biomagnetics plans to introduce into the market later this year is revolutionary in that the platform is specifically designed to be operated by personnel with only minimal training and to provide a cost per test profile significantly below that of any other competitive technology.

"We believe the receipt of this first integrated optical biosensor unit from Los Alamos will allow us to accelerate both our clinical trial and marketing efforts," commented Clayton Hardman, CEO of Biomagnetics Diagnostics. "Over the short term we plan to begin several clinical studies for malaria and tuberculosis diagnostics and to further expand our distribution reach."

Source:

 Biomagnetics Diagnostics Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine